XML 206 R59.htm IDEA: XBRL DOCUMENT v3.25.1
Equity Method Investments (Details) - USD ($)
2 Months Ended 3 Months Ended 11 Months Ended 12 Months Ended
Feb. 26, 2025
Feb. 26, 2025
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Feb. 09, 2024
Feb. 09, 2023
Equity Method Investments [Line Items]                  
Equity Method Investment, Amount       $ 12,095,020 $ 10,636,544 $ 12,095,020    
Impairment loss           454,679    
Purchased interests     20,666,667     20,666,667      
Preferred stock, value          
Equity method investment payable         666,667 666,667    
Cost of investment                 $ 19,460,000
Estimated useful life     15 years     15 years      
Intangible assets   $ 111,156   $ 166,733 611,356 $ 666,932      
Recognized impairment loss $ 0     160,788 9,196,682 259,579      
Lab services MSO’s net income   $ 503,833   $ 274,202          
Identified intangible assets         9,392,644 8,725,712 9,392,644    
Goodwill         259,579 $ 0 259,579    
Epicon Biotech Co. Ltd [Member]                  
Equity Method Investments [Line Items]                  
Equity Method Investment, Amount         0   0    
Impairment loss             454,679    
Investment in Epicon Biotech Co., Ltd. [Member]                  
Equity Method Investments [Line Items]                  
Impairment loss             $ (454,679)    
Lab Services MSO [Member]                  
Equity Method Investments [Line Items]                  
Ownership percentage     40.00%     40.00%      
Distribution of earnings from investment         0 $ 611,888      
Lab Services MSO [Member]                  
Equity Method Investments [Line Items]                  
Lab services MSO’s net income     $ 40   $ 1,236,391 79,923      
Series A Convertible Preferred Stock [Member]                  
Equity Method Investments [Line Items]                  
Preferred stock, value     9,000,000     9,000,000      
Series B Convertible Preferred Stock [Member]                  
Equity Method Investments [Line Items]                  
Preferred stock, value     $ 11,000,000     $ 11,000,000      
Issuance shares (in Shares)     11,000     11,000      
Conversion price per share (in Dollars per share)     $ 56.7     $ 56.7      
Aggregate of common stock (in Shares)     194,004     194,004      
Series B Stated Value [Member]                  
Equity Method Investments [Line Items]                  
Equity method investment payable               $ 666,667  
Minimum [Member] | Lab Services [Member]                  
Equity Method Investments [Line Items]                  
Ownership percentage           40.00%      
Maximum [Member] | Lab Services [Member]                  
Equity Method Investments [Line Items]                  
Ownership percentage           60.00%      
Series B Stated Value [Member]                  
Equity Method Investments [Line Items]                  
Preferred stock, value     $ 1,000     $ 1,000      
Avalon Shangai [Member]                  
Equity Method Investments [Line Items]                  
Total ownership percentage 40.00% 40.00%     40.00%   40.00%    
Jiangsu Unicorn Biological Technology Co., Ltd.[Member]                  
Equity Method Investments [Line Items]                  
Total ownership percentage 60.00% 60.00%     60.00%   60.00%